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abstract
Background: Inﬂuenza is associated with substantial morbidity and mortality in pregnant women and
neonates, but few countries offer annual inﬂuenza vaccination with the inactivated vaccine to all women
who are, or intend to become, pregnant.
Objectives: To provide seroepidemiological information on inﬂuenza A and B antibodies in pregnant
women and their offspring in Germany.
Study design: Anti-inﬂuenza antibodies were determined using commercially available enzyme-linked
immunosorbent assays (ELISA) on serum obtained from 209 women and their newborns at delivery.
Results: The prevalence of antibodies against inﬂuenza A virus was 93.8% [89.6–96.6%] in the mothers and
96.7% [93.2–98.6%] in the newborns. The prevalence of antibodies against inﬂuenza B virus was 42.1%
[35.3–49.1%]inthemothersand78.5%[72.3–83.8%]intheirnewborns,whichwasasigniﬁcantdifference.
The antibody concentrations against both inﬂuenza A and inﬂuenza B viruses were signiﬁcantly lower in
mother than in their newborns.
Conclusions: Because of active placental transport of IgG antibodies, neonates have higher prevalence
and/or concentrations of inﬂuenza A and B virus-speciﬁc antibodies induced by natural infections than
their mothers. Considering these serological ﬁndings, especially the lower prevalence of maternal anti-
body against inﬂuenza B virus, annual inﬂuenza vaccination may improve the protection of pregnant
women and their offspring against inﬂuenza.
© 2009 Elsevier B.V. All rights reserved.
1. Background
The most signiﬁcant respiratory infection that affects pregnant
women with the risk of severe illness and death is inﬂuenza.
Women of child-bearing age have increased exposure to young
children who have a high prevalence of infection during inﬂuenza
epidemics.1 The rate of seasonal inﬂuenza infection during the
secondandthirdtrimesterisreportedtorangefrom2%to22%.2 Epi-
demiological studies during the past 25 years document increased
rates of inﬂuenza in pregnant women compared with healthy non-
pregnant women.3,4 Inﬂuenza-associated excess deaths among
pregnant women were documented during the pandemic “Spanish
Flu” of 1918–1919 and the pandemic “Asian Flu” of 1957–1958.5,6
Providingpregnantwomenwithannualinﬂuenzavaccinationis
considered the most effective public health intervention to prevent
inﬂuenza during pregnancy. The American College of Obstetri-
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cians and Gynecologists (ACOG), along with the Centers for Disease
Control and Prevention, recommend that all women who are, or
intend to become, pregnant during the inﬂuenza season should be
vaccinated with the inactivated inﬂuenza vaccine.7,8 In Germany,
inﬂuenza vaccine is not recommended for pregnant women.9 Such
a policy would not only be beneﬁcial for pregnant women, but
their offspring might also be protected by placentally transmit-
ted maternal antibodies during the ﬁrst months of life.10 Inﬂuenza
in neonates and very young children is associated with substan-
tialmorbidityandoccasionalmortality.11,12 Ratesofhospitalization
during the inﬂuenza season are highest in very young children,
particularly those under 6 months of age, and in high-risk elderly
patients.13,14
2. Objectives
The objective of this study was to provide information on the
prevalence of inﬂuenza A and B antibodies in pregnant women and
their offspring in selected populations in Germany.
1386-6532/$ – see front matter © 2009 Elsevier B.V. All rights reserved.
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3. Study design
3.1. Subjects and serum samples
AllhealthywomenwhodeliveredattheDistrictHospitalRudol-
stadt, German federal state Thuringia, between January 1999 and
January 2000, and their healthy newborn infants agreed to be con-
secutively enrolled in this study. At delivery, the women and their
offspringwereclinicallyhealthyandroutinelaboratoryparameters
were normal. Two hundred and nine women aged between 17 and
40 years (mean 26.1 years, standard deviation, SD 4.3) and their
offspring were included in this study. One hundred and eighty-
nine (89.0%) infants were delivered spontaneously; 13 (6.2%) by
caesarean section; and 10 (4.8%) by vacuum extraction, at gesta-
tional age of 34–42 weeks (mean 39.8 weeks, SD 1.3). Data on
maternal occupation and history of inﬂuenza immunization were
not available. Blood samples were taken from all women at the
time of delivery and from the umbilical cord of the neonates by the
gynaecologist shortly after birth. Contamination of newborn blood
withmaternalbloodwasavoided.Maternalandnewbornserawere
obtained without delay by centrifugation and stored in aliquots of
0.5mlat−20 ◦Cforseveralyearsunderequalconditionsthatwould
not lead to concentration of the infant samples. Informed consent
was obtained from the parents of the infants.
3.2. Serological testing
The Inﬂuenza Virus A IgG ELISA (no. INFG0290, lots INFAG-023
and INFAG-27) and Inﬂuenza Virus B IgG ELISA (no. INFG0300, lots
INFBG-024 and INFBG-29) manufactured by NovaTec Immundi-
agnostica (Dietzenbach, Germany) were used for qualitative and
semi-quantitative antibody testing. The micro-titration strip wells
were pre-coated with inﬂuenza virus type-speciﬁc antigens con-
sisting of matrix proteins and nucleoproteins of inﬂuenza A virus
strain Texas 1/77 (H3N2) and inﬂuenza B virus strain Hong Kong
5/72, respectively. Testing of sera was carried out according to the
manufacturer’s instructions. In short, sera diluted 1 in 100 were
incubated with antigen-coated wells, washed, and incubated with
horseradish peroxidase-labeled anti-human IgG. The wells were
then washed, after which they were incubated with tetramethyl-
benzidine substrate; sulfuric acid was added to stop the reaction.
Plates were read photometrically at 450 and 620nm. Samples were
considered positive if the absorbance value was higher than 10%
above the cut-off. Negative samples had an absorbance value lower
than 10% below the cut-off. Samples with an absorbance value less
10% above or below the cut-off were regarded as equivocal. By
using the arbitrary units “NovaTec Units” (NTU), a relative quan-
titation within the test was possible. The NTU was calculated with
the following formula:
mean absorbance × 10
cut-off
= [NovaTec Units = NTU]
The cut-off was deﬁned by the manufacturer as 10NTU; posi-
tiveseracontained>11NTUandnegativeseracorrespondedtoNTU
levels of <9. For exact semi-quantitative determination of antibod-
ies, sera which showed absorbance values equal to or greater than
2.400 were re-tested on the basis of linear regression analysis after
dilution of 1:2, 1:5 and 1:10, respectively.
According to the manufacturer’s information, the perfor-
mance of the inﬂuenza A and the inﬂuenza B virus ELISA was
assessed using the VIR-ELISA Anti-Inﬂuenza A-IgG and VIR-ELISA
Anti-Inﬂuenza B-IgG (Viro-Immun Labor-Diagnostika, Oberusel,
Germany), respectively. The Inﬂuenza Virus A IgG ELISA had 93%
speciﬁcity and 96% sensitivity, whereas the Inﬂuenza Virus B IgG
ELISA had 87% speciﬁcity and 96% sensitivity.
3.3. Statistical analysis
Antibody prevalence was deﬁned as any detectable antibody.
The prevalence was calculated within the groups of mothers and
newborns as the number of seropositive cases divided by the num-
ber of subjects. Assuming binominal distribution, the two-sided
exact 95% conﬁdence intervals (CI 95%) were calculated. Differ-
ences of the antibody prevalence between the mothers and their
newborns were investigated by the McNemar test. Using the Wald
statisticsofthelogisticregressionmodel,theinﬂuenceofthedeliv-
ery method or the gestational age on the prevalence of antibodies
was examined for the neonates. Mother–newborn pair differences
of antibody concentrations were analyzed by the paired t-test
assuming approximately normal distribution. By two-way analysis
of variance, the inﬂuence of the delivery method, and the gesta-
tional age on the concentrations of antibodies was determined. The
level of signiﬁcance was 0.05 (two-sided). SAS V9.1 software was
used for statistical analyses.
4. Results
IgG antibodies against inﬂuenza A virus were detected in 193
of 209 (92.3%) paired maternal–newborn samples (Table 1). Anti-
bodies were detected in 93.8% [89.6–96.6%] of mothers and 96.7%
[93.2–98.6%] of newborns (p=0.146). Because of this high preva-
lence, the inﬂuence of the delivery method and gestational age on
the prevalence of antibodies in the newborns could not be eval-
uated. IgG antibodies against inﬂuenza B virus were present in
86 (41.2%) maternal–newborn pairs (Table 2). Antibodies against
inﬂuenza B virus were detected in 42.1% [35.3–49.1%] of mothers
and 78.5% [72.3–83.8%] of newborns (p<0.001). There was a rel-
atively high number (18.2%) of positive sera in newborns whose
mothershadequivocalresults.TheIgGprevalenceagainstinﬂuenza
B virus in newborns did not correlate with method of delivery
(p=0.067) or gestational age (p=0.763).
Antibody concentrations against inﬂuenza A virus were signiﬁ-
cantlylower(p<0.001)inthemothers(23.9NTU,SD11.2NTU)than
in the newborns (29.4NTU, SD 15.1NTU). There was no correlation
of delivery method (p=0.377) or gestational age (p=0.190) with
antibody concentration in the newborns. Antibody concentration
against inﬂuenza B virus was also signiﬁcantly lower (p<0.001) in
themothers(10.7NTU,SD4.1NTU)thaninthenewborns(14.4NTU,
Table 1
Distribution of qualitative IgG antibody against inﬂuenza A virus (IAV) in newborns compared with their mothers. The numbers represent the absolute numbers of newborns
tested negative, positive or equivocal for IAV antibodies. Percentages are given in parenthesis.
Antibodies against IAV of mothers Antibodies against IAV of newborns Summary
Negative Positive Equivocal
Negative 3(1.4%) 4(1.9%) 0(0%) 7(3.4%)
Positive 2(1.0%) 193(92.3%) 1(0.5%) 196(93.8%)
Equivocal 0(0%) 5(2.4%) 1(0.5%) 6(2.9%)
Summary 5(2.4%) 202(96.7%) 2(1.0%) 209(100%)P. Wutzler et al. / Journal of Clinical Virology 46 (2009) 161–164 163
Table 2
Distribution of qualitative IgG antibody against inﬂuenza B virus (IBV) in newborns compared with their mothers. The numbers represent the absolute numbers of newborns
tested negative, positive or equivocal for IBV antibodies. Percentages are given in parenthesis.
Antibodies against IBV of mothers Antibodies against IBV of newborns Summary
Negative Positive Equivocal
Negative 29(13.9%) 40(19.1%) 11(5.3%) 80(38.3%)
Positive 2(1.0%) 86(41.2%) 0(0%) 88(42.1%)
Equivocal 3(1.4%) 38(18.2%) 0(0%) 41(19.6%)
Summary 34(16.3%) 164(78.5%) 11(5.3%) 209(100%)
Fig.1. BoxplotofIgGantibodyconcentration[NovaTec-Units,NTU]againstinﬂuenza
Avirus(IAV)andinﬂuenzaBvirus(IBV)inmothers(m)andnewborns(n)atthetime
of delivery showing median, 25th and 75th percentile, minimum, maximum and/or
outliers (values >1.5 inter-quartile range from the end of the box).
SD 5.1NTU). Gestational age did not signiﬁcantly inﬂuence IgG
concentrations against inﬂuenza B virus in the infants (p=0.314).
However, newborns who were delivered by vacuum extraction
(n=10) had signiﬁcantly lower antibody concentrations (11.4NTU,
SD 5.4NTU) than newborns who were delivered spontaneously
(n=189, 14.5NTU, SD 5.0NTU) or by caesarean section (n=1 3;
14.5NTU, SD 6.1NTU) (p=0.046). Figs. 1 and 2 demonstrate the dis-
tribution of IgG antibody concentrations against inﬂuenza A and
inﬂuenza B virus in the mothers and newborns at the time of birth.
5. Discussion
Thehemagglutinationinhibition(HI)assayandthecomplement
ﬁxation (CF) test are used routinely for quantitation of inﬂuenza
virus-speciﬁcserumantibodies.15 However,theseassaysarelabori-
ous, difﬁcult to incorporate into automatic procedures, and require
a readily available source of appropriate erythrocytes. ELISAs mea-
suring virus-speciﬁc serum IgG antibodies are more sensitive than
the HI or the CF assay.16–18 Thus, they are more suitable for the
determination of prevalence of antibodies against inﬂuenza A and
inﬂuenza B viruses. Furthermore, since the matrix and nucleopro-
tein antigens used in these ELISAs are highly conserved within
both the inﬂuenza A and inﬂuenza B viruses,19–21 we could detect
antibodies induced by inﬂuenza A and B viruses circulating dur-
ing the last few years without subtype-speciﬁc assay. The ELISA
assays do not require the annual adjustment of the viral anti-
gen preparations and are not affected by antibodies induced by
hemagglutinin antigens of split inﬂuenza vaccines that are used
currently in Germany. A limitation is that quantitative results
cannot be calibrated in the absence of an international stan-
Fig. 2. Boxplot of mother–newborn pair differences of IgG antibody concentration
[NovaTec-Units, NTU] against inﬂuenza A virus (IAV) and inﬂuenza B virus (IBV) at
thetimeofdeliveryshowingmedian,25thand75thpercentile,minimum,maximum
and/or outliers (values >1.5 inter-quartile range from the end of the box).
dard. Thus, the arbitrary NovaTec Units were used. Even though
antibodies to inﬂuenza virus matrix and nucleoprotein antigens
may not contribute to protection, they indicate the presence of
subtype-independent T cell-mediated protection22 and may be
informative for the development and application of a new live
attenuated inﬂuenza vaccine inducing both humoral and cellular
immunity.
Inthepresentstudy,theprevalenceoftheanti-inﬂuenzaBvirus-
speciﬁc antibodies was signiﬁcantly greater in neonates than in
their mothers. In addition, the antibody concentrations against the
inﬂuenza A virus as well as the inﬂuenza B virus were signiﬁcantly
higher in newborns than in their mothers. The mean newborn-to-
mother ratios between cord and maternal blood were between 1.2
and 1.5 for antibodies against inﬂuenza A virus and between 1.3
and 1.7 for antibodies against inﬂuenza B virus. These data suggest
active placental transfer of maternal inﬂuenza virus-speciﬁc IgG
during the third trimester of pregnancy. Apart from the quantita-
tivedifferences,theprevalenceofinﬂuenzaBantibodyinnewborns
supports this hypothesis. As shown in Table 2,1 1s e r af r o mn e w -
borns whose mothers were seronegative had equivocal results and
38newbornswhosemothershadequivocalresultstestedantibody-
positive. Thus, a higher prevalence of antibodies in the cord blood
sera can be the consequence of actively transported antibodies if
maternalconcentrationswerebelowthedetectableassaylevels.No
signiﬁcant association of antibody concentration with gestational
age was found for either inﬂuenza virus A or B. This is most likely
because only 10 out of 209 babies were born at a gestational age of
≤37 weeks and only 3 after <37 weeks gestation.
Active placental transfer of maternal inﬂuenza antibody has
not been well described in a cohort of healthy women and164 P. Wutzler et al. / Journal of Clinical Virology 46 (2009) 161–164
their offspring, but has been reported for antibodies to measles,
mumps, rubella, parainﬂuenza and varicella-zoster viruses, as well
astetanusantitoxin,diphtheriaantitoxinandanti-Bordetellapertus-
sis antibodies.23–28 Speciﬁc receptor-mediated binding of the Fc
portion of IgG at the maternal surface of the placenta has been
considered part of the mechanism involved in neonatal antibody
levels.29 Why newborns who were delivered by vacuum extrac-
tionhadsigniﬁcantlylowerantibodylevelsthanneonatesdelivered
spontaneously or by caesarean section cannot be explained. Since
only 10 newborns delivered by vacuum extraction were included
in this study, the analysis of different factors that could have biased
this result is not possible.
The high prevalence of inﬂuenza A virus-speciﬁc antibodies
in pregnant women suggests high incidence of recent infection.
DependingonthepersistenceofELISAantibodies,theseresultscor-
respond to the epidemiological situation in 1999 and 2000 when
the sera included in this study were taken from the mothers and
their newborns. During these seasons, there was a moderate activ-
ityofinﬂuenzaAvirusesofthesubtypeH3N2inGermany.30,31 Since
womenatchild-bearingagehaveincreasedexposuretoyoungchil-
dren who have higher infection rates of inﬂuenza than adults,32,33
it is likely that these women have an increased risk of becoming
infected with inﬂuenza. However, this does not apply to women
havingtheirﬁrstchild.Theconsequenceofthehighantibodypreva-
lence of pregnant women is that nearly all neonates also acquired
antibodies. In the case of inﬂuenza, passive immunity is important
sincecurrentlyavailableinﬂuenzavaccinesarenotindicatedbelow
6 months of age.
In contrast, there was a lower prevalence of maternal antibody
against inﬂuenza B virus, which also reﬂects the epidemiological
data reported in 1999 and 2000 in Germany. Whereas one third
of all isolated inﬂuenza viruses could be classiﬁed as inﬂuenza B
viruses in 1999, only a few inﬂuenza B virus isolates were obtained
in the following season.30,31,34 This would lead to a relatively low
number of booster infections caused by the inﬂuenza B virus dur-
ing these seasons. Although less common and usually associated
withlowermortalitythaninﬂuenzaA,inﬂuenzaBcancausesigniﬁ-
cant morbidity and mortality in neonates and other children.11,35,36
Offering inﬂuenza vaccine to pregnant women, who will deliver
during inﬂuenza season, may potentially reduce the frequency and
severity of this neonatal disease.
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